Prophylactic Effects of Agomelatine for Poststroke Depression

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 420 participants.

Also called NCT05426304

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 420 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05426304
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05426304. Randomized; quadruple masking; primary purpose prevention. Start 2022-10-01 (anticipated); primary completion 2024-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prophylactic Effects of Agomelatine for Poststroke Depression
Acronym
PRAISED
Condition
Depression
Condition
Acute Ischemic Stroke
Intervention (Drug)
Agomelatine
Intervention (Drug)
Placebo Tablets
Lead sponsor
First Affiliated Hospital, Sun Yat-Sen University (class: other)

Record details

Record id
cardio:ct-nct05426304
Content hash
91632f240a8ee2c895cfee2634ebe0b90a7b13b0358f8b0b496ac162ce9228ca